Avalo Therapeutics AVTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's total liabilities?
- Avalo Therapeutics (AVTX) reported total liabilities of $31.57M in Q1 2026.
- How has Avalo Therapeutics's total liabilities changed year-over-year?
- Avalo Therapeutics's total liabilities increased by 98.4% year-over-year, from $15.91M to $31.57M.
- What is the long-term trend for Avalo Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total liabilities has grown at a 11.7% compound annual growth rate (CAGR), from $19.19M to $33.41M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.